miR-1 has further been reported to be down-regulated and suggested a tumor-suppressive function by targeting the transgelin 2 gene (TAGLN2) in bladder cancer [32] and head and neck squamous cell carcinomas [33]. The gene discussed is TAGLN2; the disease is urinary bladder cancer.